Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spanish phase 3 induction and maintenance comparison in newly diagnosed symptomatic multiple myeloma
2005-001110-41Phase 3Active
- Sponsor
- PETHEMA
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, thalidomide, dexamethasone and interferon alfa-2b in multiple myeloma (MM) (6 arms), sponsored by PETHEMA. Primary endpoints: Response rate during induction, Duration of response during induction and 2 more. Started Oct 2005; status: active.
02
Drugs
bortezomibthalidomidedexamethasoneinterferon alfa-2b
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-001110-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001110-41.